 Otonomy, Inc. OTIC, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from the companys gene therapy collaboration with Applied Genetic Technologies Corporation AGTC that support the selection of a product candidate for development as a treatment for gap junction beta-2 GJB2 deficiency, the most common cause of congenital hearing loss. Working with AGTC, we have identified novel and proprietary capsids that are capable of transducing support cells of the cochlea, which are the relevant target cells for treating GJB2 deficiency, said David A. Weber, Ph.D., president and chief executive officer of Otonomy. 